AFT's disclosure lacks candour despite chair's pedigree

AFT's disclosure lacks candour despite chair's pedigree
AFT Pharmaceuticals chair David Flacks has a strong background in regulation and governance.
Jenny Ruth
It's hard to fathom that AFT Pharmaceuticals' management and board only realised late on the company's balance date that it was going to miss its earnings guidance by as much as 50%.Founder and managing director Hartley Atkinson assured BusinessDesk that is what happened.AFT has two distinct revenue streams. Licensing agreements and milestone payments are by nature lumpy, and it's easy to understand that Atkinson and his team may have been expecting deals to be signed by March 31, only to see the timing slip a couple of weeks or...

More Markets

SOE wanted to close NZ's only gas trading platform immediately
Markets

SOE wanted to close NZ's only gas trading platform immediately

Transpower said the closure would make no difference; the sector disagreed.

Arvida buyout lifts retirement sector
Property

Arvida buyout lifts retirement sector

On Tuesday, Arvida traded volumes of $127 million. Its competitors followed suit.

NZ sharemarket up nearly 1% amid ongoing takeover drama
Markets Market close

NZ sharemarket up nearly 1% amid ongoing takeover drama

The S&P/NZX 50 Index closed at 12,425.58, up 115.67 points or 0.94%.

Graham Skellern 23 Jul 2024
ForBarr downgrades Genesis on gas uncertainty
Markets

ForBarr downgrades Genesis on gas uncertainty

The company faced the greatest challenges in the sector. 

Ian Llewellyn 23 Jul 2024